Salesforce Friends ...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.52 0.04 | 1.01%
06/04/12 - 12:30 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 75.70M | -92.33M | -139.56M | -162.85M |
| Operating Gains/Losses | -2.25M | -8.20M | 7.77M | -17.29M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -24.29M | 5.97M | -8.50M | 201.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -5.56M | -9.44M | 9.01M | 6.96M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -245.59M | -38.79M | 86.91M | 127.70M |
| Other Non-Cash Items | 25.39M | 31.27M | 24.52M | 23.85M |
| Net Cash From Continuing Operations | -159.23M | -101.05M | -14.59M | -9.76M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -159.23M | -101.05M | -14.59M | -9.76M |
| Sale of Property, Plant & Equipment | 1.53M | 165.00K | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 55.20M | 140.35M | 50.53M | 126.94M |
| Purchases of Property, Plant & Equipment | -991.00K | -1.81M | -5.91M | -15.13M |
| Acquisitions | 3.01M | 9.00M | 2.20M | 9.00M |
| Purchases of Short-Term Investments | 0.00 | -167.32M | -161.17M | -2.66M |
| Other Cash from Investing Activities | -110.21M | 0.00 | -2.43M | 3.22M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -51.46M | -19.57M | -112.32M | 121.37M |
| Issuance of Debt | 2.59M | 165.01M | 5.00M | 13.62M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 193.54M | 5.82M | 4.10M | 4.46M |
| Repayment of Long-Term Debt | -8.62M | -39.56M | -43.06M | -17.45M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | -25.00K | 0.00 |
| Net Cash From Financing Activities | 187.51M | 131.26M | -33.99M | 630.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -23.18M | 10.64M | -160.90M | 112.24M |
Portfolios with EXEL
- Portfolio NameUser Type
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserASCO 2010
- UserBartwaldon Portfolio 1
- UserPART 3 JPMorgan 28th Annual...
Latest EXEL Headlines from TheStreet
- ASCO 2012 Live Blog -- Sunday 06.03.12 | 07:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- Exelixis' Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript) 05.17.12 | 06:05 pm
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Exelixis' Management Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 08:05 pm
- Friday's Top 10 Articles, Videos on TheStreet 05.04.12 | 01:05 pm
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript 05.03.12 | 10:05 pm
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
Press Releases for EXEL
- Cabozantinib Meets Primary Endpoint Of Progression Free Survival In Phase 3 Pivotal Trial In Medullary Thyroid Cancer - Business Wire 06.04.12 | 12:06 pm
- Cabozantinib Demonstrates Evidence Of Anti-Tumor Effects In Heavily Pretreated Patients With Hepatocellular Carcinoma - Business Wire 06.02.12 | 06:06 pm
- Cabozantinib Demonstrates Encouraging Activity In Patients With Heavily Pretreated Metastatic Renal Cell Carcinoma - Business Wire 06.02.12 | 05:06 pm
- Exelixis Announces June 6th Webcast Of Presentation At The Goldman Sachs 33rd Annual Global Healthcare Conference - Business Wire 05.31.12 | 05:05 pm
- Exelixis Initiates COMET-1 Pivotal Trial Focused On Overall Survival In Men With Advanced Prostate Cancer - Business Wire 05.30.12 | 06:05 am
- Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Medullary Thyroid Cancer - Business Wire 05.30.12 | 06:05 am
- Reminder: Exelixis Announces Data Presentations, Webcast Of Investor Briefing In Conjunction With 2012 ASCO Annual Meeting - Business Wire 05.16.12 | 06:05 am
- Exelixis Expands The Cabozantinib Development Program Through NCI-CTEP Collaboration - Business Wire 05.03.12 | 06:05 am
- Exelixis Announces May 8th Webcast Of Presentation At The Deutsche Bank Securities 37th Annual Health Care Conference - Business Wire 05.02.12 | 04:05 pm
- Exelixis Announces May 3rd Webcast Of First Quarter 2012 Financial Results Conference Call - Business Wire 04.19.12 | 04:04 pm
Partner Headlines for EXEL
- Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- UPDATE: Piper Jaffray Downgrades Exelixis to Neutral - Benzinga 11.01.11 | 09:11 am
- Notable Put Options Activity in Exelixis - Benzinga 10.28.11 | 01:10 pm
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- Biotech Gem Exelixis Is Compelling Only for the Long Term - Seeking Alpha 08.19.11 | 05:08 pm
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Exelixis extends timeline for thyroid cancer data - Reuters 07.06.11 | 04:07 pm
